Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 20;13(4):303-311.
doi: 10.1002/cmdc.201700752. Epub 2018 Jan 19.

Helenalin Analogues Targeting NF-κB p65: Thiol Reactivity and Cellular Potency Studies of Varied Electrophiles

Affiliations

Helenalin Analogues Targeting NF-κB p65: Thiol Reactivity and Cellular Potency Studies of Varied Electrophiles

John C Widen et al. ChemMedChem. .

Abstract

Helenalin is a pseudoguaianolide natural product that targets Cys38 within the DNA binding domain of NF-κB transcription factor p65 (RelA). Helenalin contains two Michael acceptors that covalently modify cysteines: a α-methylene-γ-butyrolactone and a cyclopentenone. We recently reported two simplified helenalin analogues that mimic the biological activity of helenalin and contain both electrophilic moieties. To determine the individual contributions of the Michael acceptors toward NF-κB inhibition, we synthesized a small library of helenalin-based analogues containing various combinations of α-methylene-γ-butyrolactones and cyclopentenones. The kinetics of thiol addition to a subset of the analogues was measured to determine the relative thiol reactivities of the embedded electrophiles. Additionally, the cellular NF-κB inhibitory activities of the analogues were determined to elucidate the contributions of each Michael acceptor to biological potency. Our studies suggest the α-methylene-γ-butyrolactone contributes most significantly to the NF-κB inhibition of our simplified helenalin analogues.

Keywords: Michael acceptors; bis-electrophiles; cysteine reactive; helenalin; p65/RelA transcription factor.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(top) Helenalin is a pseudoguaianolide natural product with two Michael acceptors. 1a and 1b mimic the biological activity of helenalin.[9b] (bottom) We report a synthesis of helenalin analogues with varied Michael acceptors, the kinetic reactivities of helenalin analogues to thiols, and the NF-κB inhibitory activities of a number of helenalin analogues.
Figure 2
Figure 2
Simplified helenalin derivatives 1a (left spectra) and 1b (right spectra) were reacted with cysteamine in DMSO-d6.[12] The reactivities of the cyclopentenone and α-methylene-γ-butyrolactone of 1a and 1b were qualitatively assessed by 1H NMR analyses of protons H1–H4 as a function of cysteamine concentration and time. Reversibility of cysteamine adducts were determined by dilution studies with CDCl3. Proton signals were normalized to a TMS internal standard. These data are representative of three independent experiments.
Scheme 1
Scheme 1
Reduction of the exocyclic methylene on derivatives 2 and 3.
Scheme 2
Scheme 2
Synthesis of simplified helenalin analogues 920.

Similar articles

Cited by

References

    1. Xiao G, Fu J. Am. J. Cancer Res. 2011;1:192–221. - PMC - PubMed
    2. Aggarwal BB. Cancer Cell. 2004;6:203–208. - PubMed
    3. Herrington FD, Carmody RJ, Goodyear CS. J. Biomol. Screen. 2016;21:223–242. - PubMed
    4. Van der Heiden K, Cuhlmann S, Luong le A, Zakkar M, Evans PC. Clin. Sci. 2010;118:593–605. - PubMed
    5. Basseres DS, Baldwin AS. Oncogene. 2006;25:6817–6830. - PubMed
    6. Hayden MS, Ghosh S. Cell. 2008;132:344–362. - PubMed
    7. Huxford T, Ghosh G. Cold Spring Harbor Perspect. Biol. 2009;1:a000075. - PMC - PubMed
    1. Gilmore TD, Herscovitch M. Oncogene. 2006;25:6887–6899. - PubMed
    1. Darnell JE., Jr Nat. Rev. Cancer. 2002;2:740–749. - PubMed
    2. Berg T. Curr. Opin. Chem. Biol. 2008;12:464–471. - PubMed
    3. Koehler AN. Curr. Opin. Chem. Biol. 2010;14:331–340. - PMC - PubMed
    1. Lagoutte R, Patouret R, Winssinger N. Curr. Opin. Chem. Biol. 2017;39:54–63. - PubMed
    2. Huhn AJ, Guerra RM, Harvey EP, Bird GH, Walensky LD. Cell Chem. Biol. 2016;23:1123–1134. - PMC - PubMed
    3. Lagoutte R, Serba C, Abegg D, Hoch DG, Adibekian A, Winssinger N. Nat. Comm. 2016;7:12470. - PMC - PubMed
    4. Potashman MH, Duggan ME. J. Med. Chem. 2009;52:1231–1246. - PubMed
    5. Singh J, Petter RC, Baillie TA, Whitty A. Nat. Rev. Drug Discov. 2011;10:307–317. - PubMed
    1. Jackson PA, Widen JC, Harki DA, Brummond KM. J. Med. Chem. 2017;60:839–885. - PMC - PubMed

Publication types

LinkOut - more resources